bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Data from A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
Authors: Hayashi Hidetoshi , Sugawara Shunichi , Fukuda Yasushi , Fujimoto Daichi , Miura Satoru , Ota Keiichi , Ozawa Yuichi , Hara Satoshi , Tanizaki Junko , Azuma Koichi , Omori Shota , Tachihara Motoko , Nishino Kazumi , Bessho Akihiro , Chiba Yasutaka , Haratani Koji , Sakai Kazuko , Nishio Kazuto , Yamamoto Nobuyuki , Nakagawa Kazuhiko
Published: April 2023

Supplementary Data from A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
Supplementary Figure from A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent
Authors: Markowski Mark C. , Tutrone Ronald , Pieczonka Christopher , Barnette K. Gary , Getzenberg Robert H. , Rodriguez Domingo , Steiner Mitchell S. , Saltzstein Daniel R. , Eisenberger Mario A. , Antonarakis Emmanuel S.
Published: April 2023

Supplementary Figure from A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent
Supplementary Table from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung Trial
Authors: Barlesi Fabrice , Tomasini Pascale , Karimi Maryam , Michiels Stefan , Raimbourg Judith , Daniel Catherine , Janicot Henri , Madroszyk Anne , Audigier-Valette Clarisse , Quoix Elisabeth , Mazieres Julien , Moro-Sibilot Denis , Dansin Eric , Molinier Olivier , Morel Hugues , Pichon Eric , Cortot Alexis , Otto Josiane , Chomy François , Souquet Pierre-Jean , Cloarec Nicolas , Giroux-Leprieur Etienne , Bieche Ivan , Lacroix Ludovic , Boyault Sandrine , Attignon Valery , Soubeyran Isabelle , Morel Alain , Tran-Dien Alicia , Jacquet Alexandra , Dall'Olio Filippo Gustavo , Jimenez Marta , Soria Jean-Charles , Besse Benjamin
Published: April 2023

Supplementary Table from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung Trial
Supplementary Table from Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication
Authors: Inaba Hiroto , van Oosterwijk Jolieke G. , Panetta John C. , Li Lie , Buelow Daelynn R. , Blachly James S. , Shurtleff Sheila , Pui Ching-Hon , Ribeiro Raul C. , Rubnitz Jeffrey E. , Pounds Stanley , Baker Sharyn D.
Published: April 2023

Supplementary Table from Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication
Supplementary Data from Phase II Clinical Trial of Eribulin–Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma
Authors: Kim Chang Gon , Sim Nam Suk , Kim Jeong Eun , Yun Kum-Hee , Lee Young Han , Kim Seung Hyun , Baek Wooyeol , Han Yoon Dae , Kim Sang Kyum , Kim Jee Hung , Koh Yoon Woo , Jung Inkyung , Shin Su-Jin , Rha Sun Young , Ahn Jin-Hee , Kim Hyo Song
Published: April 2023

Supplementary Data from Phase II Clinical Trial of Eribulin–Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma
Supplementary Data from Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression
Authors: Hemming Matthew L. , Bhola Patrick , Loycano Michael A. , Anderson Justin A. , Taddei Madeleine L. , Doyle Leona A. , Lavrova Elizaveta , Andersen Jessica L. , Klega Kelly S. , Benson Morgan R. , Crompton Brian D. , Raut Chandrajit P. , George Suzanne , Letai Anthony , Demetri George D. , Sicinska Ewa
Published: April 2023

Supplementary Data from Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression
Supplementary Figure from Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer
Authors: Durinikova Erika , Reilly Nicole M. , Buzo Kristi , Mariella Elisa , Chilà Rosaria , Lorenzato Annalisa , Dias João M. L. , Grasso Gaia , Pisati Federica , Lamba Simona , Corti Giorgio , Degasperi Andrea , Cancelliere Carlotta , Mauri Gianluca , Andrei Pietro , Linnebacher Michael , Marsoni Silvia , Siena Salvatore , Sartore-Bianchi Andrea , Nik-Zainal Serena , Di Nicolantonio Federica , Bardelli Alberto , Arena Sabrina
Published: April 2023

Supplementary Figure from Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer
Supplementary Data from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Authors: Cheng Vinton W.T. , de Pennington Nicholas , Zakaria Rasheed , Larkin James R. , Serres Sébastien , Sarkar Manjima , Kirkman Matthew A. , Bristow Claire , Croal Paula , Plaha Puneet , Campo Leticia , Chappell Michael A. , Lord Simon , Jenkinson Michael D. , Middleton Mark R. , Sibson Nicola R.
Published: April 2023

Supplementary Data from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Supplementary Figure S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Authors: Hebron Katie E. , Wan Xiaolin , Roth Jacob S. , Liewehr David J. , Sealover Nancy E. , Frye William J.E. , Kim Angela , Stauffer Stacey , Perkins Olivia L. , Sun Wenyue , Isanogle Kristine A. , Robinson Christina M. , James Amy , Awasthi Parirokh , Shankarappa Priya , Luo Xiaoling , Lei Haiyan , Butcher Donna , Smith Roberta , Edmondson Elijah F. , Chen Jin-Qiu , Kedei Noemi , Peer Cody J. , Shern Jack F. , Figg W. Douglas , Chen Lu , Hall Matthew D. , Difilippantonio Simone , Barr Frederic G. , Kortum Robert L. , Robey Robert W. , Vaseva Angelina V. , Khan Javed , Yohe Marielle E.
Published: April 2023

Schematic depicting the impact of PTEN loss on sensitivity to MEK inhibition
Supplementary Figure S5 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Authors: Hebron Katie E. , Wan Xiaolin , Roth Jacob S. , Liewehr David J. , Sealover Nancy E. , Frye William J.E. , Kim Angela , Stauffer Stacey , Perkins Olivia L. , Sun Wenyue , Isanogle Kristine A. , Robinson Christina M. , James Amy , Awasthi Parirokh , Shankarappa Priya , Luo Xiaoling , Lei Haiyan , Butcher Donna , Smith Roberta , Edmondson Elijah F. , Chen Jin-Qiu , Kedei Noemi , Peer Cody J. , Shern Jack F. , Figg W. Douglas , Chen Lu , Hall Matthew D. , Difilippantonio Simone , Barr Frederic G. , Kortum Robert L. , Robey Robert W. , Vaseva Angelina V. , Khan Javed , Yohe Marielle E.
Published: April 2023

Mechanism of decreased PTEN expression in RD
Appendix Table A1 from Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study
Authors: An Jusheng , Tang Jie , Li Benjamin X. , Xiong Huihua , Qiu Hui , Luo Lin , Wang Li , Wang Danbo , Zhou Qi , Xu Qin , Song Honglin , Zhang Yunyan , Zhang Hongping , Li Yujie , Yu Xiaohui , Zhang Jing , Ng Rachel , Zhao Wayne , Wong Michael , Dai Xiangrong , Li Guiling , Wu Lingying
Published: April 2023

Anti-Tumor Efficacy Assessment using iRECIST criteria by IRC Evaluation
Supplementary Figure S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Authors: Hebron Katie E. , Wan Xiaolin , Roth Jacob S. , Liewehr David J. , Sealover Nancy E. , Frye William J.E. , Kim Angela , Stauffer Stacey , Perkins Olivia L. , Sun Wenyue , Isanogle Kristine A. , Robinson Christina M. , James Amy , Awasthi Parirokh , Shankarappa Priya , Luo Xiaoling , Lei Haiyan , Butcher Donna , Smith Roberta , Edmondson Elijah F. , Chen Jin-Qiu , Kedei Noemi , Peer Cody J. , Shern Jack F. , Figg W. Douglas , Chen Lu , Hall Matthew D. , Difilippantonio Simone , Barr Frederic G. , Kortum Robert L. , Robey Robert W. , Vaseva Angelina V. , Khan Javed , Yohe Marielle E.
Published: April 2023

Combining ganitumab with trametinib inhibits tumor growth and increases fibrosis in SMS-CTR but not RD xenografts
Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Authors: Hebron Katie E. , Wan Xiaolin , Roth Jacob S. , Liewehr David J. , Sealover Nancy E. , Frye William J.E. , Kim Angela , Stauffer Stacey , Perkins Olivia L. , Sun Wenyue , Isanogle Kristine A. , Robinson Christina M. , James Amy , Awasthi Parirokh , Shankarappa Priya , Luo Xiaoling , Lei Haiyan , Butcher Donna , Smith Roberta , Edmondson Elijah F. , Chen Jin-Qiu , Kedei Noemi , Peer Cody J. , Shern Jack F. , Figg W. Douglas , Chen Lu , Hall Matthew D. , Difilippantonio Simone , Barr Frederic G. , Kortum Robert L. , Robey Robert W. , Vaseva Angelina V. , Khan Javed , Yohe Marielle E.
Published: April 2023

Related to Figure 4
Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Authors: Hebron Katie E. , Wan Xiaolin , Roth Jacob S. , Liewehr David J. , Sealover Nancy E. , Frye William J.E. , Kim Angela , Stauffer Stacey , Perkins Olivia L. , Sun Wenyue , Isanogle Kristine A. , Robinson Christina M. , James Amy , Awasthi Parirokh , Shankarappa Priya , Luo Xiaoling , Lei Haiyan , Butcher Donna , Smith Roberta , Edmondson Elijah F. , Chen Jin-Qiu , Kedei Noemi , Peer Cody J. , Shern Jack F. , Figg W. Douglas , Chen Lu , Hall Matthew D. , Difilippantonio Simone , Barr Frederic G. , Kortum Robert L. , Robey Robert W. , Vaseva Angelina V. , Khan Javed , Yohe Marielle E.
Published: April 2023

Related to Figure 2 - RD
Supplementary Data File S5 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Authors: Hebron Katie E. , Wan Xiaolin , Roth Jacob S. , Liewehr David J. , Sealover Nancy E. , Frye William J.E. , Kim Angela , Stauffer Stacey , Perkins Olivia L. , Sun Wenyue , Isanogle Kristine A. , Robinson Christina M. , James Amy , Awasthi Parirokh , Shankarappa Priya , Luo Xiaoling , Lei Haiyan , Butcher Donna , Smith Roberta , Edmondson Elijah F. , Chen Jin-Qiu , Kedei Noemi , Peer Cody J. , Shern Jack F. , Figg W. Douglas , Chen Lu , Hall Matthew D. , Difilippantonio Simone , Barr Frederic G. , Kortum Robert L. , Robey Robert W. , Vaseva Angelina V. , Khan Javed , Yohe Marielle E.
Published: April 2023

Baseline Statistics
Figure 1 FS1 from FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures
Authors: Sridharan Vishwajith , Neyaz Azfar , Chogule Abhijit , Baiev Islam , Reyes Stephanie , Barr Fritcher Emily G. , Lennerz Jochen K. , Sukov William , Kipp Benjamin , Ting David T. , Deshpande Vikram , Goyal Lipika
Published: April 2023

Supplementary Figure 1
Supplementary Figures S1-S7 from Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia
Authors: Canali Alban , Vergnolle Inès , Bertoli Sarah , Largeaud Laetitia , Nicolau Marie-Laure , Rieu Jean-Baptiste , Tavitian Suzanne , Huguet Françoise , Picard Muriel , Bories Pierre , Vial Jean Philippe , Lechevalier Nicolas , Béné Marie Christine , Luquet Isabelle , Mansat-De Mas Véronique , Delabesse Eric , Récher Christian , Vergez François
Published: April 2023

Supplemental figure 1. Flow chart for sample availability of patients included in our study and their
outcome.
Supplemental figure 2.
Supplemental figure 3. Size of LSC nodes in CD34+CD38- subpopulation in AML-CD34+ and AMLCD34- populations. Mann-Whitney test.
Supplemental figure 4. LSC phenotypic profiles according to MRD status. Normalized MFI of CD34,
CD38, CD45RA, CD135 and CD133 in LSC nodes used to measure LSC MRD. Mann-Whitney tests.
Supplemental figure 5. Landmark analysis at 6 months of the impact of HSCT according to MRD status.
Supplemental figure 6. Evaluation of immunophenotypic markers in chemoresistant and chemosensitive AML patients at diagnosis.
Supplemental figure 7. Evaluation of LSC phenotypic markers in clinically relevant AML patients in
relation to Figure 4.
Supplementary Figure from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
Authors: Mao Lili , Fang Meiyu , Chen Yu , Wei Xiaoting , Cao Jun , Lin Jing , Zhang Peng , Chen Ling , Cao Xiao , Chen Yujun , Guo Jun , Si Lu
Published: April 2023

Supplementary Figure from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
Supplementary Tables S1-5 from Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma
Authors: Paudel Sarita , Warner Benjamin E. , Wang Renwei , Adams-Haduch Jennifer , Reznik Alex S. , Dou Jason , Huang Yufei , Gao Yu-Tang , Koh Woon-Puay , Bäckerholm Alan , Yuan Jian-Min , Shair Kathy H.Y.
Published: April 2023

Table S1. Baseline demographic and lifestyle characteristics of study participants who developed nasopharyngeal carcinoma (cases) and those who remained cancer free (controls), the Singapore Chinse Health Study and the Shanghai Cohort Study; Table S2. EBV ORF Expression Library; Table S3. Anti-EBV IgA prediction or protection of NPC by EBV ORF class; Table S4. Anti-EBV IgG prediction or protection of NPC by EBV ORF class; Table S5. Detection of EBNA1 IgA in NPC cases sorted from the shortest to the longest time interval from blood collection to diagnosis of NPC, along with matched controls in the Singapore Chinese Health Study (SCHS) and the Shanghai Cohort Study (SCS).
Supplementary Data DS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
Authors: Green Daniel S. , Ning Franklin , Duemler Anna , Myers Timothy G. , Trewhitt Kathryn , Ekwede Irene , McCoy Ann , Houston Nicole , Lee Jung-min , Lipkowitz Stanley , Zimmer Alexandra , Pavelova Miroslava , Villanueva Erin N. , Smith Leslie , Blakely Andrew , Casablanca Yovanni , Highfill Steven L. , Stroncek David F. , Collins-Johnson Naoza , Panch Sandhya , Procter JoLynn , Pham Chauha , Korrapati Soumya , Holland Steven M. , Rosen Lindsey B. , Nunes Ana T. , Zoon Kathryn C. , Cole Christopher B. , Annunziata Christina M.
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 2 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1+ Macrophages and Fibroblasts
Authors: Sathe Anuja , Mason Kaishu , Grimes Susan M. , Zhou Zilu , Lau Billy T. , Bai Xiangqi , Su Andrew , Tan Xiao , Lee HoJoon , Suarez Carlos J. , Nguyen Quan , Poultsides George , Zhang Nancy R. , Ji Hanlee P.
Published: April 2023

Heatmap depicting cell states from monocytes and macrophages identified using Ecotyper NMF analysis, annotated by condition and genes with highest fold change in each state. Data from seven mCRCs, five paired normal liver tissue and two paired PBMCs.
Supplementary Table from Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine
Authors: Pollyea Daniel A. , Pratz Keith W. , Wei Andrew H. , Pullarkat Vinod , Jonas Brian A. , Recher Christian , Babu Sunil , Schuh Andre C. , Dail Monique , Sun Yan , Potluri Jalaja , Chyla Brenda , DiNardo Courtney D.
Published: April 2023

Supplementary Table from Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine
Supplementary Table 1 from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas
Authors: Jungwirth Gerhard , Yu Tao , Liu Fang , Cao Junguo , Alaa Eddine Montadar , Moustafa Mahmoud , Abdollahi Amir , Warta Rolf , Unterberg Andreas , Herold-Mende Christel
Published: April 2023

Drug Screening Data
Table S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma
Authors: Wang Jian , Weiss Tobias , Neidert Marian C. , Toussaint Nora C. , Naghavian Reza , Sellés Moreno Carla , Foege Magdalena , Tomas Ojer Paula , Medici Gioele , Jelcic Ivan , Schulz Daniel , Rushing Elisabeth , Dettwiler Susanne , Schrörs Barbara , Shin Joo Heon , McKay Ron , Wu Catherine J. , Lutterotti Andreas , Sospedra Mireia , Moch Holger , Greiner Erich F. , Bodenmiller Bernd , Regli Luca , Weller Michael , Roth Patrick , Martin Roland
Published: April 2023

Over-/highly expressed genes in the primary glioblastoma when compared with glioblastoma cohort in TCGA Database.
Figure S1 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma
Authors: Wang Jian , Weiss Tobias , Neidert Marian C. , Toussaint Nora C. , Naghavian Reza , Sellés Moreno Carla , Foege Magdalena , Tomas Ojer Paula , Medici Gioele , Jelcic Ivan , Schulz Daniel , Rushing Elisabeth , Dettwiler Susanne , Schrörs Barbara , Shin Joo Heon , McKay Ron , Wu Catherine J. , Lutterotti Andreas , Sospedra Mireia , Moch Holger , Greiner Erich F. , Bodenmiller Bernd , Regli Luca , Weller Michael , Roth Patrick , Martin Roland
Published: April 2023

Schematic outline of the personalized peptide vaccination. (A) Timeline of clinical events for a patient with glioblastoma in whom we applied a highly personalized peptide vaccination. I. Vaccine peptide design. Surgically resected primary glioblastoma and PBMCs were collected. Somatic mutants and over-/highly expressed genes in glioblastoma were identified as TSAs and TAAs by WES and RNA-seq, and the HLA genotype were identified with PBMCs by DNA sequencing. Potential vaccine peptides were predicted and selected from TSAs and TAAs based on HLA binding prediction. Peptide cocktails containing ~25 peptides for HLA class I or II molecules were prepared for vaccination. II. Peptide cocktail vaccination and testing. The patient was s.c. vaccinated with the peptide cocktails, and Imiquimod or XS15 + MontanideTM were used as the adjuvant. Meanwhile, the patient received treatment with pembrolizumab and bevacizumab. No dexamethasone was given throughout the periods of vaccination. PBMCs were collected after vaccination at the indicated time points and tested with vaccine peptides to examine the effect of immunotherapy. Surgically resected recurrent glioblastoma was collected after four vaccinations, and tumor-infiltrating lymphocytes (TILs) were isolated and tested with vaccine peptides. (B) HLA genotypes of the patient with glioblastoma, including HLA-A, HLA-B, HLA-DR, HLA-DP, and HLA-DQ alleles. n.a. indicates not available.
Supplementary Table S1 from Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer
Authors: Peng Ke , Zhang Feifei , Wang Yichen , Sahgal Pranshu , Li Tianxia , Zhou Jin , Liang Xiaoyan , Zhang Yanxi , Sethi Nilay , Liu Tianshu , Zhang Haisheng , Bass Adam J.
Published: April 2023

Antibody List
Supplementary Data from miR-196b–TLR7/8 Signaling Axis Regulates Innate Immune Signaling and Myeloid Maturation in DNMT3A-Mutant AML
Authors: Gamlen Holly A. , Romer-Seibert Jennifer S. , Lawler Michael E. , Versace Amanda M. , Goetz Melanie L. , Feng Yang , Guryanova Olga A. , Palmisiano Neil , Meyer Sara E.
Published: April 2023

Supplementary Data from miR-196b–TLR7/8 Signaling Axis Regulates Innate Immune Signaling and Myeloid Maturation in DNMT3A-Mutant AML
Figure S4 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Authors: Kang Kyung-Don , Bernstock Joshua D. , Totsch Stacie K. , Gary Sam E. , Rocco Abbey , Nan Li , Li Rong , Etminan Tina , Han Xiaosi , Beierle Elizabeth A. , Eisemann Tanja , Wechsler-Reya Robert J. , Bae Sejong , Whitley Richard , Gillespie G. Yancey , Markert James M. , Friedman Gregory K.
Published: April 2023

Toxicity with repeated doses of IVT oHSV.
Supplementary Methods 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Authors: Meagher Nicola S. , Gorringe Kylie L. , Wakefield Matthew , Bolithon Adelyn , Pang Chi Nam Ignatius , Chiu Derek S. , Anglesio Michael S. , Mallitt Kylie-Ann , Doherty Jennifer A. , Harris Holly R. , Schildkraut Joellen M. , Berchuck Andrew , Cushing-Haugen Kara L. , Chezar Ksenia , Chou Angela , Tan Adeline , Alsop Jennifer , Barlow Ellen , Beckmann Matthias W. , Boros Jessica , Bowtell David D.L. , Brand Alison H. , Brenton James D. , Campbell Ian , Cheasley Dane , Cohen Joshua , Cybulski Cezary , Elishaev Esther , Erber Ramona , Farrell Rhonda , Fischer Anna , Fu Zhuxuan , Gilks Blake , Gill Anthony J. , Gourley Charlie , Grube Marcel , Harnett Paul R. , Hartmann Arndt , Hettiaratchi Anusha , Høgdall Claus K. , Huzarski Tomasz , Jakubowska Anna , Jimenez-Linan Mercedes , Kennedy Catherine J. , Kim Byoung-Gie , Kim Jae-Weon , Kim Jae-Hoon , Klett Kayla , Koziak Jennifer M. , Lai Tiffany , Laslavic Angela , Lester Jenny , Leung Yee , Li Na , Liauw Winston , Lim Belle W.X. , Linder Anna , Lubiński Jan , Mahale Sakshi , Mateoiu Constantina , McInerny Simone , Menkiszak Janusz , Minoo Parham , Mittelstadt Suzana , Morris David , Orsulic Sandra , Park Sang-Yoon , Pearce Celeste Leigh , Pearson John V. , Pike Malcolm C. , Quinn Carmel M. , Mohan Ganendra Raj , Rao Jianyu , Riggan Marjorie J. , Ruebner Matthias , Salfinger Stuart , Scott Clare L. , Shah Mitul , Steed Helen , Stewart Colin J.R. , Subramanian Deepak , Sung Soseul , Tang Katrina , Timpson Paul , Ward Robyn L. , Wiedenhoefer Rebekka , Thorne Heather , Cohen Paul A. , Crowe Philip , Fasching Peter A. , Gronwald Jacek , Hawkins Nicholas J. , Høgdall Estrid , Huntsman David G. , James Paul A. , Karlan Beth Y. , Kelemen Linda E. , Kommoss Stefan , Konecny Gottfried E. , Modugno Francesmary , Park Sue K. , Staebler Annette , Sundfeldt Karin , Wu Anna H. , Talhouk Aline , Pharoah Paul D.P. , Anderson Lyndal , DeFazio Anna , Köbel Martin , Friedlander Michael L. , Ramus Susan J.
Published: April 2023

Supplementary Methods
Supplementary Figure S2 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
Authors: Asleh Karama , Lluch Ana , Goytain Angela , Barrios Carlos , Wang Xue Q. , Torrecillas Laura , Gao Dongxia , Ruiz-Borrego Manuel , Leung Samuel , Bines José , Guerrero-Zotano Ángel , García-Sáenz Jose Ángel , Cejalvo Juan Miguel , Herranz Jesus , Torres Roberto , Haba-Rodriguez Juan de la , Ayala Francisco , Gómez Henry , Rojo Federico , Nielsen Torsten O. , Martin Miguel
Published: April 2023

Supplementary Figure S2 shows a forest plot comparing basal vs. non-basal subtype as defined by PAM50 or by IHC, and their associations with disease free survival on capecitabine vs. observation arm.
Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Authors: Kebir Sied , Ullrich Vivien , Berger Pia , Dobersalske Celia , Langer Sarah , Rauschenbach Laurèl , Trageser Daniel , Till Andreas , Lorbeer Franziska K. , Wieland Anja , Wilhelm-Buchstab Timo , Ahmad Ashar , Fröhlich Holger , Cima Igor , Prasad Shruthi , Matschke Johann , Jendrossek Verena , Remke Marc , Grüner Barbara M. , Roesch Alexander , Siveke Jens T. , Herold-Mende Christel , Blau Tobias , Keyvani Kathy , van Landeghem Frank K.H. , Pietsch Torsten , Felsberg Jörg , Reifenberger Guido , Weller Michael , Sure Ulrich , Brüstle Oliver , Simon Matthias , Glas Martin , Scheffler Björn
Published: April 2023

Validation cohort, patient flow diagram. Patient enrollment and final inclusion of FFPE tissue samples in this study is shown. n = 3 patients were excluded from enrollment for reasons listed. The validation cohort comprised paired tissue samples from a total of n = 38 patients. Detailed characteristics in Supplementary Table S4. Note, the separate discovery cohort of paired vital cells is detailed in Supplementary Table S1. The GLASS cohort was used as an additional, external reference comprising data on n=37 patients extracted from (10).
Supplementary Table S1 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
Authors: Serra-Camprubí Queralt , Verdaguer Helena , Oliveros Winona , Lupión-Garcia Núria , Llop-Guevara Alba , Molina Cristina , Vila-Casadesús Maria , Turpin Anthony , Neuzillet Cindy , Frigola Joan , Querol Jessica , Yáñez-Bartolomé Mariana , Castet Florian , Fabregat-Franco Carles , Escudero-Iriarte Carmen , Escorihuela Marta , Arenas Enrique J. , Bernadó-Morales Cristina , Haro Noemí , Giles Francis J. , Pozo Óscar J. , Miquel Josep M. , Nuciforo Paolo G. , Vivancos Ana , Melé Marta , Serra Violeta , Arribas Joaquín , Tabernero Josep , Peiró Sandra , Macarulla Teresa , Tian Tian V.
Published: April 2023

Genomic alterations and gene fusions included in the VHIO-300 panel.
Figure S1 from Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study
Authors: Liu Xin , Jiang Shiyu , Wang Huijie , Wu Xianghua , Yan Wangjun , Chen Yong , Xu Yu , Wang Chunmeng , Yao Weiqiang , Wang Jian , Yu Lin , Miao Jiashun , Chen Hao , Xia Jing , Huang Mengli , Zhang Xiaowei , Luo Zhiguo
Published: April 2023

Figure S1. No significant change was observed in LVEF at baseline and after treatment (p=0.669,
Kruskal-Wallis rank sum test).
Supplementary Table S1: FDA Benefit Risk Assessment and Summary from FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor
Authors: Kumar Vaibhav , Doros Leslie , Thompson Margaret , Mushti Sirisha L. , Charlab Rosane , Spehalski Elizabeth I. , Zhao Hong , Thompson Matthew D. , Tang Shenghui , Pazdur Richard , Lemery Steven J. , Theoret Marc R. , Fashoyin-Aje Lola A.
Published: April 2023

FDA Benefit Risk Assessment and Summary
Supplementary Figure from Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer
Authors: Ruggieri Amanda N. , Yarchoan Mark , Goyal Subir , Liu Yuan , Sharon Elad , Chen Helen X. , Olson Brian M. , Paulos Chrystal M. , El-Rayes Bassel F. , Maithel Shishir K. , Azad Nilofer S. , Lesinski Gregory B.
Published: April 2023

Supplementary Figure from Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer
supplementary table legend1 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
Authors: Milewski David , Jung Hyun , Brown G. Thomas , Liu Yanling , Somerville Ben , Lisle Curtis , Ladanyi Marc , Rudzinski Erin R. , Choo-Wosoba Hyoyoung , Barkauskas Donald A. , Lo Tammy , Hall David , Linardic Corinne M. , Wei Jun S. , Chou Hsien-Chao , Skapek Stephen X. , Venkatramani Rajkumar , Bode Peter K. , Steinberg Seth M. , Zaki George , Kuznetsov Igor B. , Hawkins Douglas S. , Shern Jack F. , Collins Jack , Khan Javed
Published: April 2023

supplementary table legend
Supplementary_Methods1 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
Authors: Milewski David , Jung Hyun , Brown G. Thomas , Liu Yanling , Somerville Ben , Lisle Curtis , Ladanyi Marc , Rudzinski Erin R. , Choo-Wosoba Hyoyoung , Barkauskas Donald A. , Lo Tammy , Hall David , Linardic Corinne M. , Wei Jun S. , Chou Hsien-Chao , Skapek Stephen X. , Venkatramani Rajkumar , Bode Peter K. , Steinberg Seth M. , Zaki George , Kuznetsov Igor B. , Hawkins Douglas S. , Shern Jack F. , Collins Jack , Khan Javed
Published: April 2023

Supplemental Description of the Rhabdomyosarcoma Web-based Application
supplementary legend1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Authors: Giraldo Nicolas A. , Drill Esther , Satravada Baby A. , Dika Imane El , Brannon A. Rose , Dermawan Josephine , Mohanty Abhinita , Ozcan Kerem , Chakravarty Debyani , Benayed Ryma , Vakiani Efsevia , Abou-Alfa Ghassan K. , Kundra Ritika , Schultz Nikolaus , Li Bob T. , Berger Michael F. , Harding James J. , Ladanyi Marc , O'Reilly Eileen M. , Jarnagin William , Vanderbilt Chad , Basturk Olca , Arcila Maria E.
Published: April 2023

supplementary legend
Supplementary Data from Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis
Authors: Nagler Arnon , Ngoya Maud , Galimard Jacques-Emmanuel , Labopin Myriam , Bornhäuser Martin , Stelljes Matthias , Finke Jürgen , Ganser Arnold , Einsele Herman , Kröger Nicolaus , Brecht Arne , Bethge Wolfgang , Edinger Matthias , Kulagin Aleksandr , Passweg Jakob , Blau Igor Wolfgang , Elmaagacli Ahmet , Schäfer-Eckart Kerstin , Platzbecker Uwe , Schroeder Thomas , Bunjes Donald , Tischer Johanna , Martin Sonja , Spyridonidis Alexandros , Giebel Sebastian , Savani Bipin , Mohty Mohamad
Published: April 2023

Supplementary Data from Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis
Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Authors: Oh Seung Yeon , Lee You Won , Lee Eun Ji , Kim Jae Hwan , Park YoungJoon , Heo Seong Gu , Yu Mi Ra , Hong Min Hee , DaSilva John , Daly Christopher , Cho Byoung Chul , Lim Sun Min , Yun Mi Ran
Published: April 2023

(A-B) The surface expression levels of EGFR, MET, REGN5093 and IgG4 control of each cell were measured by flow cytometry. MFI stands for mean fluorescence intensity.
Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Authors: Oh Seung Yeon , Lee You Won , Lee Eun Ji , Kim Jae Hwan , Park YoungJoon , Heo Seong Gu , Yu Mi Ra , Hong Min Hee , DaSilva John , Daly Christopher , Cho Byoung Chul , Lim Sun Min , Yun Mi Ran
Published: April 2023

Genomic landscape in patient-derived preclinical models. The genetic alteration of the PDC (patient-derived cell), PDO (patient-derived organoid), and PDX (patient-derived xenograft) models are shown as an oncoprint plot.
Supplementary Figure S1 from Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma
Authors: Wang Jun , Guo Wei , Wang Xiaofang , Tang Xiaodong , Sun Xin , Ren Tingting
Published: April 2023

Design and flowchart of the present prospective study.
Supplementary Data 1 from Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study
Authors: Fernández-Miranda Ismael , Pedrosa Lucía , Llanos Marta , Franco Fernando F. , Gómez Sagrario , Martín-Acosta Paloma , García-Arroyo Francisco R. , Gumá Josep , Horcajo Beatriz , Ballesteros Ana K. , Gálvez Laura , Martínez Natividad , Marín Miguel , Sequero Silvia , Navarro Marta , Yanguas-Casás Natalia , Calvo Virginia , Rueda-Domínguez Antonio , Provencio Mariano , Sánchez-Beato Margarita
Published: April 2023

Supplementary Data 1
Supplementary Figures S1-S7 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
Authors: Kfir-Erenfeld Shlomit , Asherie Nathalie , Grisariu Sigal , Avni Batia , Zimran Eran , Assayag Miri , Sharon Tatyana Dubnikov , Pick Marjorie , Lebel Eyal , Shaulov Adir , Cohen Yael C. , Avivi Irit , Cohen Cyrille J. , Stepensky Polina , Gatt Moshe E.
Published: April 2023

Supplementary Figures S1-S7
Table S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Authors: Ma Yuanqing , Joyce Allison , Brandenburg Olivia , Saatchi Faeze , Stevens Christina , Toffessi Tcheuyap Vanina , Christie Alana , Do Quyen N. , Fatunde Oluwatomilade , Macchiaroli Alyssa , Wong So C. , Woolford Layton , Yousuf Qurratulain , Miyata Jeffrey , Carrillo Deyssy , Onabolu Oreoluwa , McKenzie Tiffani , Mishra Akhilesh , Hardy Tanner , He Wei , Li Daniel , Ivanishev Alexander , Zhang Qing , Pedrosa Ivan , Kapur Payal , Schluep Thomas , Kanner Steven B. , Hamilton James , Brugarolas James
Published: April 2023

Table S1
Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Authors: Ma Yuanqing , Joyce Allison , Brandenburg Olivia , Saatchi Faeze , Stevens Christina , Toffessi Tcheuyap Vanina , Christie Alana , Do Quyen N. , Fatunde Oluwatomilade , Macchiaroli Alyssa , Wong So C. , Woolford Layton , Yousuf Qurratulain , Miyata Jeffrey , Carrillo Deyssy , Onabolu Oreoluwa , McKenzie Tiffani , Mishra Akhilesh , Hardy Tanner , He Wei , Li Daniel , Ivanishev Alexander , Zhang Qing , Pedrosa Ivan , Kapur Payal , Schluep Thomas , Kanner Steven B. , Hamilton James , Brugarolas James
Published: April 2023

Figure S6
Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Authors: Ma Yuanqing , Joyce Allison , Brandenburg Olivia , Saatchi Faeze , Stevens Christina , Toffessi Tcheuyap Vanina , Christie Alana , Do Quyen N. , Fatunde Oluwatomilade , Macchiaroli Alyssa , Wong So C. , Woolford Layton , Yousuf Qurratulain , Miyata Jeffrey , Carrillo Deyssy , Onabolu Oreoluwa , McKenzie Tiffani , Mishra Akhilesh , Hardy Tanner , He Wei , Li Daniel , Ivanishev Alexander , Zhang Qing , Pedrosa Ivan , Kapur Payal , Schluep Thomas , Kanner Steven B. , Hamilton James , Brugarolas James
Published: April 2023

Figure S2
Supplementary Table S1 from Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance
Authors: Carney Stephen V. , Banerjee Kaushik , Mujeeb Anzar , Zhu Brandon , Haase Santiago , Varela Maria L. , Kadiyala Padma , Tronrud Claire E. , Zhu Ziwen , Mukherji Devarshi , Gorla Preethi , Sun Yilun , Tagett Rebecca , Núñez Felipe J. , Luo Maowu , Luo Weibo , Ljungman Mats , Liu Yayuan , Xia Ziyun , Schwendeman Anna , Qin Tingting , Sartor Maureen A. , Costello Joseph F. , Cahill Daniel P. , Lowenstein Pedro R. , Castro Maria G.
Published: April 2023

Table S1. RNA sequencing comparison data
Supplementary Figure S7 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
Authors: Janssens Katleen , Vanhoutte Greetje , Lybaert Willem , Demey Wim , Decaestecker Jochen , Hendrickx Koen , Rezaei Kalantari Hassan , Zwaenepoel Karen , Pauwels Patrick , Fransen Erik , Op de Beeck Ken , Van Camp Guy , Rolfo Christian , Peeters Marc
Published: April 2023

Copy number alteration (CNA) profile of patient 24 based on shallow whole-genome sequencing (sWGS) of the baseline cfDNA sample.
Supplementary Figure S3 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
Authors: Janssens Katleen , Vanhoutte Greetje , Lybaert Willem , Demey Wim , Decaestecker Jochen , Hendrickx Koen , Rezaei Kalantari Hassan , Zwaenepoel Karen , Pauwels Patrick , Fransen Erik , Op de Beeck Ken , Van Camp Guy , Rolfo Christian , Peeters Marc
Published: April 2023

Kaplan Meier curve for overall survival.
Figure S1 from Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Authors: Debie Yana , Van Audenaerde Jonas R.M. , Vandamme Timon , Croes Lieselot , Teuwen Laure-Anne , Verbruggen Lise , Vanhoutte Greetje , Marcq Elly , Verheggen Lisa , Le Blon Debbie , Peeters Bart , Goossens Maria E. , Pannus Pieter , Ariën Kevin K. , Anguille Sébastien , Janssens Annelies , Prenen Hans , Smits Evelien L.J. , Vulsteke Christof , Lion Eva , Peeters Marc , van Dam Peter A.
Published: April 2023

Supplementary Figure 1: Correlation betweenSARS-CoV-2 anti-S1 IgG antibody titers and NT50 values against
Wuhan and BA.1 Omicron strains post homologous or heterologous booster vaccination in cancer patients and
healthy individuals.
Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Authors: Visvanathan Kala , Cope Leslie , Fackler Mary Jo , Considine Michael , Sokoll Lori , Carey Lisa A. , Forero-Torres Andres , Ingle James N. , Lin Nancy U. , Nanda Rita , Storniolo Anna Maria , Tulac Suzana , Venkatesan Neesha , Wu Natalie C. , Marla Sudhakar , Campbell Scott , Bates Michael , Umbricht Christopher B. , Wolff Antonio C. , Sukumar Saraswati
Published: April 2023

Supplementary figure 5 displays time updated ROC curves for (A) CM level at week 8, (B) Change in CM level (Week8 – Week4) and (C) the Combination of week 8 CM level and Change in CM level (Week 8-Week 4) using linear discriminant analysis.
Supplementary Tables S1-14 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations
Authors: Sivakumar Smruthy , Jin Dexter X. , Rathod Ruchita , Ross Jeffrey , Cantley Lewis C. , Scaltriti Maurizio , Chen Jessica W. , Hutchinson Katherine E. , Wilson Timothy R. , Sokol Ethan S. , Vasan Neil
Published: April 2023

Table S1: Clinico-demographic characteristics of single- and multi-PIK3CA mutant tumors; Table S2: Prevalence of single and multi-PIK3CA mutated tumors across all tumor types; Table S3: Prevalence of single and multi-PIK3CA mutated tumors across pan-tumor histological subtypes; Table S4: Prevalence of single and multi-PIK3CA mutated tumors in different receptor subgroups of breast cancer; Table S5: Clonality predictions for double PIK3CA mutated tumors in different tumor types; Table S6: Prediction of cis/trans orientation for double PIK3CA mutated tumors in different tumor types; Table S7: Patterns of co-occurrence and mutual exclusivity between multi-PIK3CA mutations and other gene alterations in the overall cohort and specific tumor types; Table S8: Comparison of co-occurring alterations in multi-PIK3CA and single-PIK3CA mutant tumors; Table S9: Prevalence of multi-PIK3CA mutations based on status of tumor mutational burden; Table S10: Breakdown of PIK3CA mutations in different classes of mutational signatures in patients with a high tumor mutational burden; Table S11: Prevalence of single- and multi-PIK3CA mutations based on tumor mutational burden and APOBEC signatures; Table S12: Prevalence of specific pairs of PIK3CA mutations across different tumor types; Table S13: Prevalence of specific pairs of PIK3CA mutations at the codon level, across different tumor types; Table S14: Codon enrichment between single and multi-PIK3CA mutant tumors across different tumor types.
Supplementary Figure S7 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations
Authors: Sivakumar Smruthy , Jin Dexter X. , Rathod Ruchita , Ross Jeffrey , Cantley Lewis C. , Scaltriti Maurizio , Chen Jessica W. , Hutchinson Katherine E. , Wilson Timothy R. , Sokol Ethan S. , Vasan Neil
Published: April 2023

Serine and threonine phosphoproteome of NIH-3T3 cells bearing PIK3CA E726K/H1047R vs H1047R.
Supplementary Table S5 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Authors: Cheema Amrita K. , Li Yaoxiang , Ventimiglia Mary , Kowalczyk Keith , Hankins Ryan , Bandi Gaurav , Janowski Einsley-Marie , Grindrod Scott , Villagra Alejandro , Dritschilo Anatoly
Published: April 2023

Linear mixed effects model analysis of metabolomics data augments validation of immune response findings with proteomics.
Supplementary Figure S2 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Authors: Cheema Amrita K. , Li Yaoxiang , Ventimiglia Mary , Kowalczyk Keith , Hankins Ryan , Bandi Gaurav , Janowski Einsley-Marie , Grindrod Scott , Villagra Alejandro , Dritschilo Anatoly
Published: April 2023

Heatmap visualization of significantly dysregulated metabolites following RT.
Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Authors: Owen Dwight H. , Benner Brooke , Wei Lai , Sukrithan Vineeth , Goyal Ashima , Zhou Ye , Pilcher Carly , Suffren Sheryl-Ann , Christenson Gwen , Curtis Nancy , Jukich Megan , Schwarz Emily , Savardekar Himanshu , Norman Ruthann , Ferguson Sarah , Kleiber Barbara , Wesolowski Robert , Carson William E. , Otterson Gregory A. , Verschraegen Claire F. , Shah Manisha H. , Konda Bhavana
Published: April 2023

Evaluation of co-inhibitory molecules by patient response. Total T cells at screening and C1D15 were identified as being CD4+ or CD8+ and patients were grouped by best clinical response as partial response (PR) or non-PR. The percentage of each T cell subset expressing (A) PD-1, (B) LAG3, (C) TIM3, and (D) KLRG3 at screening and C1D15 are shown. * p < 0.05.
Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Authors: Owen Dwight H. , Benner Brooke , Wei Lai , Sukrithan Vineeth , Goyal Ashima , Zhou Ye , Pilcher Carly , Suffren Sheryl-Ann , Christenson Gwen , Curtis Nancy , Jukich Megan , Schwarz Emily , Savardekar Himanshu , Norman Ruthann , Ferguson Sarah , Kleiber Barbara , Wesolowski Robert , Carson William E. , Otterson Gregory A. , Verschraegen Claire F. , Shah Manisha H. , Konda Bhavana
Published: April 2023

Evaluation of circulating CD8+ cell subsets. (A) Changes in levels of circulating CD8+ naïve (CD45RA+ CCR7+), central memory (CM; CD45RA- CCR7+), effector memory (EM; CD45RA- CCR7-), and terminal effector memory (TE; CD45RA+ CCR7-) subsets at screening and cycle 1, day 15 (C1D15) of nivolumab and temozolomide treatment in the entire study cohort. (B) Levels of co-inhibitory molecules PD-1, LAG3, TIM3, and KLRG1 on circulating CD8+ T cells on study treatment compared to screening. Each symbol represents one patient (n = 9). Line indicates mean, *p<0.05
Figure S8 from Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases
Authors: Von Roemeling Christina A. , Doonan Bently P. , Klippel Kelena , Schultz Daniel , Hoang-Minh Lan , Trivedi Vrunda , Li Chenglong , Russell Rylynn A. , Kanumuri Raju S. , Sharma Abhisheak , Tun Han W. , Mitchell Duane A.
Published: April 2023

Supplemental Figure 8. (a) Representative IHC for Ki67 proliferative marker (pink pseudocolor) in B16F10 MBM tumors isolated on day 7 of treatment (day 12 of study) with vehicle control or CA-4948 (100 mg/kg). GFAP (astrocytes, green pseudocolor), CD45 (red pseudocolor), and DAPI nuclear stain (blue pseudocolor) included, scale bar = 100μm. (b) Quantitative comparison of Ki67 tissue expression shown in panel f between vehicle control (n=5) and CA-4948 (n=5), measured as the % of Ki67 positive cells within total cell population defined by DAPI nuclear count within the tumor area. P-value determined by unpaired t test.
Supplementary Figure 6 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
Authors: Mondello Patrizia , Paludo Jonas , Novak Joseph P. , Wenzl Kerstin , Yang Zhi-Zhang , Jalali Shahrzad , Krull Jordan E. , Braggio Esteban , Dasari Surendra , Manske Michelle K. , Abeykoon Jithma A. , Sarangi Vivekananda , Kapoor Prashant , Paulus Aneel , Reeder Craig B. , Ailawadhi Sikander , Chanan-Khan Asher A. , Kyle Robert A. , Gertz Morie A. , Novak Anne J. , Ansell Stephen M.
Published: April 2023

Supplementary Figure 6 Boxplots showing the expression of indicated metabolites in C1 (red), C2 (blue) and C3d (green). Differences between groups were calculated with the Mann-Whitney U test. ns, non-significant.
Figure S3 from Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases
Authors: Von Roemeling Christina A. , Doonan Bently P. , Klippel Kelena , Schultz Daniel , Hoang-Minh Lan , Trivedi Vrunda , Li Chenglong , Russell Rylynn A. , Kanumuri Raju S. , Sharma Abhisheak , Tun Han W. , Mitchell Duane A.
Published: April 2023

Supplemental Figure 3. Active IRAK-4 expression in intracranial tumors.
Figure S2 from Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases
Authors: Von Roemeling Christina A. , Doonan Bently P. , Klippel Kelena , Schultz Daniel , Hoang-Minh Lan , Trivedi Vrunda , Li Chenglong , Russell Rylynn A. , Kanumuri Raju S. , Sharma Abhisheak , Tun Han W. , Mitchell Duane A.
Published: April 2023

Supplemental Figure 2. CA-4948 affinity for murine IRAK-4.
Supplementary Figure 4 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
Authors: Mondello Patrizia , Paludo Jonas , Novak Joseph P. , Wenzl Kerstin , Yang Zhi-Zhang , Jalali Shahrzad , Krull Jordan E. , Braggio Esteban , Dasari Surendra , Manske Michelle K. , Abeykoon Jithma A. , Sarangi Vivekananda , Kapoor Prashant , Paulus Aneel , Reeder Craig B. , Ailawadhi Sikander , Chanan-Khan Asher A. , Kyle Robert A. , Gertz Morie A. , Novak Anne J. , Ansell Stephen M.
Published: April 2023

Supplementary Figure 4. Schematic representation of the mechanism associated with the three clusters.
Supplementary figure 2 from Characterization of Cell-Free DNA Size Distribution in Osteosarcoma Patients
Authors: Udomruk Sasimol , Phanphaisarn Areerak , Kanthawang Thanat , Sangphukieo Apiwat , Sutthitthasakul Songphon , Tongjai Siripong , Teeyakasem Pimpisa , Thongkumkoon Patcharawadee , Orrapin Santhasiri , Moonmuang Sutpirat , Klangjorhor Jeerawan , Pasena Arnat , Suksakit Pathacha , Dissook Sivamoke , Puranachot Pitithat , Settakorn Jongkolnee , Pusadee Tonapha , Pruksakorn Dumnoensun , Chaiyawat Parunya
Published: April 2023

Supplementary figure 2. Gel image analysis demonstrated the distribution of cfDNA fragment size in plasma from (A) healthy donors (n=15) and (B) osteosarcoma (n=50). (C) Comparison of cfDNA fragment size distribution pattern between healthy control, patient with osteosarcoma stage IIb, and osteosarcoma stage III. All results were analyzed by QIAxcel screengel software.
Supplementary Figure S2 from Preoperative Neutrophil-to-Lymphocyte Ratio and a New Inflammatory Biomarkers Prognostic Index for Primary Retroperitoneal Sarcomas: Retrospective Monocentric Study
Authors: Fiore Marco , Ljevar Silva , Pasquali Sandro , Morelli Daniele , Callegaro Dario , Sanfilippo Roberta , Barisella Marta , Sangalli Claudia , Miceli Rosalba , Gronchi Alessandro
Published: April 2023

Supplemental Figure 2. Association of IBPI with postoperative serious complications Clavien-Dindo grade 3 or higher.
Supplementary Figure S1 from Preoperative Neutrophil-to-Lymphocyte Ratio and a New Inflammatory Biomarkers Prognostic Index for Primary Retroperitoneal Sarcomas: Retrospective Monocentric Study
Authors: Fiore Marco , Ljevar Silva , Pasquali Sandro , Morelli Daniele , Callegaro Dario , Sanfilippo Roberta , Barisella Marta , Sangalli Claudia , Miceli Rosalba , Gronchi Alessandro
Published: April 2023

Supplemental Figure 1. Relationship between the risk of death, expressed as log-relative hazard from multivariable Cox model, and inflammation-related serum biomarkers.